duramycin and Nasopharyngeal-Neoplasms

Male BALB/c mice bearing NPC xenografts were randomized into four groups (six mice each group). Group 1 received radiotherapy (RT, 15 Gy/mouse) in combination with cetuximab (CTX, 2 mg/mouse), group 2 received RT (15 Gy/mouse), group 3 was treated using CTX (2 mg/mouse), and group 4, the control group, was treated using a vehicle.. After 24 h treatment,. We demonstrated that RT in combination with CTX treatment significantly improved disease control in a NPC xenograft model compared with monotherapy with either.

Topics: Animals; Antineoplastic Agents, Immunological; Bacteriocins; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides; Technetium; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays